Only LIPITOR® Is LIPITOR.

There Is No Generic Form of LIPITOR

Medicines can work differently in different people. So switching to a different medication may not be right for you. If you switch from LIPITOR to generic Zocor® (simvastatin), you may not get the same cholesterol-lowering results you get with LIPITOR. While there are generic versions of other cholesterol-lowering medications, there is no approved generic form of LIPITOR.

Talk to your doctor about staying with what is working for you—LIPITOR.

LIPITOR is the #1 prescribed branded medication in the world*

It's important to do what you can for your heart health. That's why you and your doctor decided on LIPITOR.

LIPITOR is FDA-approved to significantly reduce the risk of:

  • Heart attack
  • Stroke
  • Certain kinds of heart surgeries
  • Chest pain
if you have several common risk factors, including high blood pressure, low HDL ("good" cholesterol), family history, smoking, and age.

 

Five times more physicians surveyed would recommend LIPITOR to their own family members over other cholesterol-lowering medications.

LIPITOR is one of the most widely studied medicines in the world—with more than 15 years of research.

  • Over 400 ongoing and completed clinical studies—which included over 80,000 patients

LIPITOR has a proven safety record.

If LIPITOR is working for you, why switch?
Before you consider switching to another medication, it's important to learn more.

If you switch, you may not get the same cholesterol-lowering results you get with LIPITOR.

  • LIPITOR is proven to lower LDL ("bad" cholesterol)
    76 to 115 points, or 39%-60% (average effect
    depending on dose)
  • The cholesterol level you've achieved could change
Other things to consider:
  • Your body could respond differently to a different medication
  • You may need additional blood tests and checkups

In clinical studies, LIPITOR lowered bad cholesterol significantly more than generic Zocor (simvastatin).

Zocor is a registered trademark of Merck & Co, Inc.

*IMS Health. IMS National Prescription Audit Plus. March 2006.
Results are based on a blinded, national, random survey of 493 physicians representative of the AMA master file, conducted by Harris Interactive Inc. April-June 2007.
Data on file. Pfizer Inc, New York, NY.